Main Menu

The "Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination" represents a cutting-edge approach in the realm of immunization technology. This innovative platform utilizes meticulously engineered nanoparticles, comprised of self-assembling proteins, to present the coronavirus's distinctive spike proteins to the immune system. These nanoparticles are uniquely designed to attach to an immunogenic segment of the virus, ensuring that this critical component is effectively exhibited on the nanoparticle surface.

This innovative technology revolves around a novel vaccine development strategy for combating filoviruses, notorious for causing severe hemorrhagic fevers in humans and non-human primates. At the heart of this advancement is a modified vaccinia Ankara (MVA) vector, ingeniously engineered to encode specific viral antigens that trigger a protective immune response against various filoviruses, including the Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), and the Marburg virus.

The inventors have developed an RNA Zika vaccine construct using the self-amplifying mRNA (SAM®) vaccine platform. This technology combines the GSK SAM mRNA delivery vector system with the VRC’s Zika proteins to optimize immune responses against Zika virus, with the ultimate goal of preventing infection. The vaccine is designed to elicit strong and durable immune responses, potentially offering a promising approach to combat Zika virus disease. The current development stage of this technology is likely in the pre-clinical or early clinical stages of testing.

The technology involves the use of Modified Vaccinia Ankara (MVA) as a vaccine vector for HIV. MVA is a safe and immunogenic poxvirus vector that can accommodate large gene insertions. In this case, researchers have modified MVA to express a functional B13R gene, which helps delay apoptosis (cell death) of infected cells. This modification aims to enhance the immune response against HIV. The technology has shown promise in pre-clinical studies, demonstrating its potential as a candidate for an HIV vaccine.

The technology involves the development of viral hemagglutinin (HA) mutants that enhance the binding affinity to sialic acid (SA) receptors on host cell surfaces. This enhanced interaction is achieved by introducing specific mutations into the HA protein, leading to increased immunogenicity and vaccine efficacy. The mutated HA proteins are then incorporated into ferritin nanoparticles, which serve as a delivery platform to enhance protein production and stability. This technology shows promise in improving vaccine design and efficacy against viral infections.

This technology entails a novel vaccine design against malaria, employing an alphavirus Virus-Like Particle (VLP) system to present a critical epitope from the Plasmodium falciparum circumsporozoite protein (PfCSP). The vaccine targets the junctional region between the N-terminus and the central repeat domain of PfCSP, a segment previously identified as vital for generating protective immunity.

This innovative HIV immunization strategy relies on mRNA technology to prime and boost immune responses, using full-length or minimally truncated Env proteins to maintain native conformation for effective membrane expression. Co-formulating Env and Gag proteins promotes virus-like particle (VLP) production in vivo, mimicking HIV's structure for better immune recognition. The regimen involves an intensive schedule of 8+ sequential immunizations and includes boosting with diverse Envs from different HIV-1 clades to broaden the immune response.

The CIS43 antibody represents a cutting-edge advancement in the fight against malaria, a disease caused by Plasmodium parasites and transmitted by mosquitoes. CIS43 targets the junctional epitope of the Plasmodium falciparum circumsporozoite protein, showing promising efficacy in preventing malaria infection in controlled human infection-based studies. The latest developments have focused on generating improved variants of CIS43 with enhanced protective capabilities.

The technology described pertains to the development of bispecific antibodies with enhanced ability to neutralize HIV-1. By structurally designing single chain fragment variable antibodies that join variable regions of multiple broadly neutralizing antibodies (bNAbs) with flexible linkers, the research has yielded a bispecific antibody that targets different epitopes on the HIV-1 envelope. The combination of VRC01—targeting the CD4 binding site—and PGT121—targeting the V3 glycan—has shown promising results.

The development of an infectious molecular clone of simian immunodeficiency virus SIVsm, known as SIVsmE543-3, marks a significant breakthrough in SIV research. This clone, derived from a late-stage biological isolate from an immunodeficient rhesus macaque with SIV-induced encephalitis, has shown robust replication in macaque immune cells and macrophages. Notably, SIVsmE543-3 exhibits resistance to neutralization by heterologous sera, which can typically neutralize genetically diverse SIV variants in vitro.